About Glutamate-rich WD repeat-containing protein 1
Glutamate-rich WD repeat-containing protein 1 (GRWD1) is a protein
from Homo sapiens identified by UniProt accession
Q9BQ67, 446 residues long.
MolForge cross-references it against 0 known binders and
38 disease associations.
Target properties
| Protein name | Glutamate-rich WD repeat-containing protein 1 |
| UniProt accession | Q9BQ67 |
| Gene | GRWD1 |
| Organism | Homo sapiens |
| Length | 446 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (38)
Diseases linked to this target (Open Targets).
- neurodegenerative disease · score 0.47
- prostate carcinoma · score 0.11
- prostate cancer · score 0.11
- Familial prostate cancer · score 0.11
- colon carcinoma · score 0.07
- neoplasm · score 0.07
- cancer · score 0.07
- triple-negative breast cancer · score 0.05
- lung adenocarcinoma · score 0.02
- non-small cell lung carcinoma · score 0.02
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q9BQ67-F1 | alphafold | PREDICTED | 88.81 | — |
Amino-acid sequence (446 residues)
MAARKGRRRT CETGEPMEAE SGDTSSEGPA QVYLPGRGPP LREGEELVMD EEAYVLYHRA QTGAPCLSFD IVRDHLGDNR TELPLTLYLC AGTQAESAQS NRLMMLRMHN LHGTKPPPSE GSDEEEEEED EEDEEERKPQ LELAMVPHYG GINRVRVSWL GEEPVAGVWS EKGQVEVFAL RRLLQVVEEP QALAAFLRDE QAQMKPIFSF AGHMGEGFAL DWSPRVTGRL LTGDCQKNIH LWTPTDGGSW HVDQRPFVGH TRSVEDLQWS PTENTVFASC SADASIRIWD IRAAPSKACM LTTATAHDGD VNVISWSRRE PFLLSGGDDG ALKIWDLRQF KSGSPVATFK QHVAPVTSVE WHPQDSGVFA ASGADHQITQ WDLAVERDPE AGDVEADPGL ADLPQQLLFV HQGETELKEL HWHPQCPGLL VSTALSGFTI FRTISV
Explore Glutamate-rich WD repeat-containing protein 1 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets